Bristol Myers Squibb manufactures Nivolumab [1]. Nivolumab is marketed under the brand name Opdivo [2].
What is Opdivo used for?
Opdivo is an immunotherapy drug that works by blocking the PD-1 protein. This helps the immune system recognize and attack cancer cells [3]. It is approved for the treatment of various cancers, including melanoma, lung cancer, kidney cancer, bladder cancer, and certain types of lymphoma and colorectal cancer [4].
When does Opdivo's patent expire?
The patent landscape for Opdivo is complex and involves multiple patents covering different aspects of the drug, including its composition, method of use, and manufacturing [5]. Exclusivity periods can vary significantly depending on the specific patent and geographic region [5]. For detailed information on patent expiry dates for Opdivo, resources like DrugPatentWatch.com can provide a comprehensive overview [5].
Can biosimilars be made for Opdivo?
The development of biosimilars for Opdivo is possible once patents and other exclusivities expire [6]. However, the process of bringing a biosimilar to market is lengthy and requires demonstrating similarity in terms of safety, efficacy, and quality to the reference product [6]. Competition from biosimilars could potentially lower drug costs [7].